Abstract
NGAL (Neutrophil Gelatinase-Associated Lipocalin) is a small 25-kD peptide belonging to the lipocalin superfamily. Several studies highlight its role as an organ injury and disease activity biomarker. In the present review, instead, we wanted to study NGAL as a precocious marker of therapeutic response in renal and non-renal diseases (glomerulonephritis, vasculitis, LES, Crohns disease and other chronic inflammatory pathologies). The obtained outcomes support the hypothesis that NGAL could be employed as a biomarker of response to different therapeutic schemes, because its levels sensibly and precociously change compared to other haematologic and biochemical parameters.
Keywords: NGAL, acute renal failure, chronic kidney disease, clinical nephrology, clinical pharmacology, glomerulonephritis, vasculitis, antimicrobial, gentamicin, microalbuminuria, Crohn's disease, flogistic, Infliximab, idiopathic, streptozotocin, angiotensin, sepsis, inefficacy, etiologic, immunosuppressors
Current Pharmaceutical Design
Title: NGAL is a Precocious Marker of Therapeutic Response
Volume: 17 Issue: 8
Author(s): Valeria Cernaro, Davide Bolignano, Valentina Donato, Antonio Lacquaniti, Antoine Buemi, Eleonora Crascì, Silvia Lucisano and Michele Buemi
Affiliation:
Keywords: NGAL, acute renal failure, chronic kidney disease, clinical nephrology, clinical pharmacology, glomerulonephritis, vasculitis, antimicrobial, gentamicin, microalbuminuria, Crohn's disease, flogistic, Infliximab, idiopathic, streptozotocin, angiotensin, sepsis, inefficacy, etiologic, immunosuppressors
Abstract: NGAL (Neutrophil Gelatinase-Associated Lipocalin) is a small 25-kD peptide belonging to the lipocalin superfamily. Several studies highlight its role as an organ injury and disease activity biomarker. In the present review, instead, we wanted to study NGAL as a precocious marker of therapeutic response in renal and non-renal diseases (glomerulonephritis, vasculitis, LES, Crohns disease and other chronic inflammatory pathologies). The obtained outcomes support the hypothesis that NGAL could be employed as a biomarker of response to different therapeutic schemes, because its levels sensibly and precociously change compared to other haematologic and biochemical parameters.
Export Options
About this article
Cite this article as:
Cernaro Valeria, Bolignano Davide, Donato Valentina, Lacquaniti Antonio, Buemi Antoine, Crascì Eleonora, Lucisano Silvia and Buemi Michele, NGAL is a Precocious Marker of Therapeutic Response, Current Pharmaceutical Design 2011; 17 (8) . https://dx.doi.org/10.2174/138161211795428939
DOI https://dx.doi.org/10.2174/138161211795428939 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Modern Treatment of Infection and Ischaemia to Reduce Major Amputation in the Diabetic Foot
Current Pharmaceutical Design Animal Models of Diabetes Mellitus: Relevance to Vascular Complications
Current Pharmaceutical Design Identification of Novel Anti-inflammatory Agents from Ayurvedic Medicine for Prevention of Chronic Diseases: “Reverse Pharmacology” and “Bedside to Bench” Approach
Current Drug Targets Role of Isoprenoid Compounds on Angiogenic Regulation: Opportunities and Challenges
Current Medicinal Chemistry Sjogrens Syndrome and Lymphoma Development
Current Immunology Reviews (Discontinued) In Vitro Inhibition Of Three Different Drugs Used In Rheumatoid Arthritis Treatment On Human Serum Paraoxanase 1 Enzyme Activity
Protein & Peptide Letters Antiplatelet Therapy in Acute Coronary Syndromes. Evidence Based Medicine
Current Pharmaceutical Design TAP-Independent MHC Class I Presentation
Current Immunology Reviews (Discontinued) Medical Treatment for Neurocysticercosis: Drugs, Indications and Perspectives
Current Topics in Medicinal Chemistry In Vitro and Ex Vivo Model Systems to Measure ABC Transporter Activity at the Blood-Brain Barrier
Current Pharmaceutical Design Editorial [ Hot Topic:Stroke Bugs: Current and Emerging Concepts Relevant to Infection in Cerebrovascular Disease (Guest Editors: Hedley CA Emsley and Angel Chamorro)]
Infectious Disorders - Drug Targets Drugs, Trials and Pathogenesis: Will Connecting these Help us Understand SLE?
Current Rheumatology Reviews Association of Common Variants in the IL-33/ST2 Axis with Ischemic Stroke
Current Neurovascular Research High Sensitivity Troponin in Cardiovascular Disease. Is There More Than a Marker of Myocardial Death?
Current Topics in Medicinal Chemistry Comparison of Triflusal with Aspirin in the Secondary Prevention of Atherothrombotic Events; Α Randomised Clinical Trial
Current Vascular Pharmacology Nitric Oxide Homeostasis in Neurodegenerative Diseases
Current Alzheimer Research Survey of the State of the Art in Biomaterials, Cells, Genes and Proteins Integrated into Micro- and Nanoscaffolds for Tissue Regeneration
Current Nanoscience Pediatric CKD and Cardivascular Disease
Cardiovascular & Hematological Disorders-Drug Targets Toxic Shock Syndrome and Persistent Immune Activation in an HIVPositive Patient
Current HIV Research Testosterone as Potential Effective Therapy in Treatment of Obesity in Men with Testosterone Deficiency: A Review
Current Diabetes Reviews